

Citations and Reference Literature: Devil's Claw

Citations

1. Boje K, Lechtenberg M, Nahrstedt A. New and known iridoid- and phenylethanoid glycosides from *Harpagophytum procumbens* and their in vitro inhibition of human leukocyte elastase. *Planta Med* 2003;69:820-825.
2. Weiss R. *Herbal Medicine*. Meuss A, Translator. 6th ed. Beaconsfield, UK: Beaconsfield Publishers Ltd; 1988.
3. Blumenthal M, Busse W, Goldberg A et al. *The Complete German Commission E Monographs*. Austin, Texas: American Botanical Council; Integrative Medicine Communications; 1998.
4. ESCOP. *Harpagophytum Radix*. ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003:233-240.
5. Chrubasik S. Addendum to the ESCOP monograph on *Harpagophytum procumbens*. *Phytomedicine* 2004; 11:691-695.
6. Setty AR, Sigal LH. Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. *Semin Arthritis Rheum* 2005;34:773-784.
7. Gagnier JJ, Chrubasik S, Manheimer E. *Harpagophytum procumbens* for osteoarthritis and low back pain: a systematic review. *BMC Complement Altern Med* 2004;4:13.
8. Gagnier J, Vantulder M, Berman B, Bombardier C. Herbal medicine for low back pain. *Cochrane Database Syst Rev* 2006;CD004504.
9. Fontaine J, Elechami AA, Vanhaelen M, Vanhaelen-Fastre R. [Biological analysis of *Harpagophytum procumbens* DC. II. Pharmacological analysis of the effects of harpagoside, harpagide and harpagogenine on the isolated guinea-pig ileum (author's translation)]. *J Pharm Belg* 1981;36:321-324.
10. Grahame R, Robinson BV. Devil's claw (*Harpagophytum procumbens*): pharmacological and clinical studies. *Ann Rheum Dis* 1981;40:632.
11. Whitehouse LW, Znamirowska M, Paul CJ. Devil's claw (*Harpagophytum procumbens*): no evidence for anti-inflammatory activity in the treatment of arthritic disease. *Can Med Assoc J* 1983;129:249-251.
12. Fiebich BL, Heinrich M, Hiller KO, Kammerer N. Inhibition of TNF- α synthesis in LPS-stimulated primary human monocytes by *Harpagophytum* extract SteiHap 69. *Phytomedicine* 2001;8:28-30.
13. Loew D, Mollerfeld J, Schrodter A et al. Investigations on the pharmacokinetic properties of *Harpagophytum* extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. *Clin Pharmacol Ther* 2001;69:356-364.
14. Jang MH, Lim S, Han SM et al. *Harpagophytum procumbens* suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929. *J Pharmacol Sci* 2003;93:367-371.
15. Kundu JK, Mossanda KS, Na H-K, Surh Y-J. Inhibitory effects of the extracts of *Sutherlandia frutescens* (L.) R. Br. and *Harpagophytum procumbens* DC on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB as potential upstream targets. *Cancer Lett* 2005;218:21-31.
16. Moussard C, Alber D, Toubin MM et al. A drug used in traditional medicine, *Harpagophytum procumbens*: no evidence for NSAID-like effect on whole blood eicosanoid production in human. *Prostaglandins Leukot Essent Fatty Acids* 1992;46:283-286.
17. Huang TH-W, Tran VH, Duke RK et al. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF- κ B activation. *J Ethnopharmacol* 2006;104:149-155.
18. Chribasik JE, Lindhorst E, Neumann E et al. Potential molecular basis of the chondroprotective effect of *Harpagophytum procumbens*. *Phytomedicine* 2006;13:598-600.
19. Circosta C, Occhiuto F, Ragusa S et al. A drug used in traditional medicine: *Harpagophytum procumbens* DC. II. Cardiovascular activity. *J Ethnopharmacol* 1984;11:259-274.
20. Costa De Pasquale R, Busa G, Circosta C et al. A drug used in traditional medicine: *Harpagophytum procumbens* DC. III. Effects on hyperkinetic ventricular arrhythmias by reperfusion. *J Ethnopharmacol* 1985;13:193-199.
21. Occhiuto F, Circosta C, Ragusa S et al. A drug used in traditional medicine: *Harpagophytum procumbens* DC. IV. Effects on some isolated muscle preparations. *J Ethnopharmacol* 1985;13:201-208.
22. Mahomed IM, Ojewole JAO. Anticonvulsant activity of *Harpagophytum procumbens* DC [Pedaliaceae] secondary root aqueous extract in mice. *Brain Res Bull* 2006;69:57-62.
23. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. *Rapid Commun Mass Spectrom* 2004;18:2273-2281.
24. Chribasik S, Conradt C, Black A. The quality of clinical trials with *Harpagophytum procumbens*. *Phytomedicine* 2003;10:613-623.
25. Chribasik S, Junck H, Breitschwerdt H et al. Effectiveness of *Harpagophytum* extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double-blind study. *Eur J Anaesthesiol* 1999;16:118-129.
26. Chribasik S, Model A, Black A, Pollak S. A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. *Rheumatology (Oxford)* 2003;42:141-148.

Citations and Reference Literature: Devil's Claw

27. Chrubasik S, Pollak S, Fiebich B. Harpagophytum extracts. *Clin Pharmacol Ther* 2002;71:104-105.
28. Chrubasik S, Sporer F, Dillmann-Marschner R et al. Physicochemical properties of harpagoside and its in vitro release from Harpagophytum procumbens extract tablets. *Phytomedicine* 2000;6:469-473.
29. Chrubasik S, Thanner J, Kunzel O et al. Comparison of outcome measures during treatment with the proprietary Harpagophytum extract doloteffin in patients with pain in the lower back, knee or hip. *Phytomedicine* 2002;9:181-194.
30. Chantre P, Cappelaere A, Leblan D et al. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. *Phytomedicine* 2000;7:177-183.
31. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. *JAMA* 2001;286:954-959.
32. Zhao SZ, Reynolds MW, Lejkowith J et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. *Clin Ther* 2001;23:1478-1491.
33. Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). *Drug Saf* 1997;17:342-356.
34. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. *Br J Clin Pharmacol* 2001;52:587-595.